Biotech RadarJobs updated

COMPANY

Castle Biosciences

HQ: Friendswood, TX source · castlebiosciences.com ↗ · Southwest

FDA-cleared device company

Profile checked Oct 10, 2026

Keywords: Cutaneous Melanoma Atopic Dermatitis Uveal Melanoma Rectal Adenocarcinoma Anal Adenocarcinoma Anal Squamous Cell Carcinoma Nevisense electrical impedance spectroscopy

5Trials (company is sponsor)

Timeline

  1. Trial start —: Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares source ↗
  2. Trial start —: Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays source ↗
  3. Trial start —: 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results source ↗
  4. Trial start —: Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes source ↗
  5. Trial start —: 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07645820Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis FlaresNot listedRecruitingJun 4, 2026Apr 1, 2027 (estimated)
NCT023769205 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient OutcomesNot listedCompleted2010-032022-04 (actual)
NCT023555745-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay ResultsNot listedTerminated2014-062021-02 (actual)
NCT02355587Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient OutcomesNot listedTerminated2014-032021-07 (actual)
NCT02407561Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression AssaysNot listedTerminated2015-022016-07 (actual)
Feedback